Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Avalo Therapeutics is attractive because its lead asset, abdakibart, produced positive Phase II LOTUS data in hidradenitis suppurativa, with HiSCR-75 of 42.5%-45.2% and a placebo-adjusted benefit of roughly 17-19.4 points, supporting the anti-IL-1β thesis and lowering clinical risk. The company also appears financially secure, with about $472 million of cash and investments as of May 31 funding operations into 2029, which should allow it to advance end-of-Phase 2 regulatory discussions in 2H26 and Phase 3 initiation in 1H27 without near-term dilution pressure. Beyond abdakibart, the pipeline includes AVTX-010, quisovalimab, AVTX-008, AVTX-006, and AVTX-913, giving it multiple shots on goal in immune-mediated inflammatory diseases and enhancing long-term optionality.

Avalo Therapeutics is a clinical-stage biotech that still depends on abdakibart and a handful of early programs, so its valuation remains highly sensitive to clinical execution, safety readthroughs, and competitive benchmarks such as HiSCR75. The company’s 2Q26 financing lifted cash, cash equivalents, and investments to $472.2M from $82.0M and is expected to fund operations into 2029, but OpEx rose 50.8% to $31.5M and net loss widened 85.2% to $36.4M, underscoring continued burn. Even with longer-term optionality from AVTX-010 planned for 1H27, downside risk is driven by delays, negative data, failure to achieve approval, slower commercial uptake, and possible long-term equity dilution.